 |
|
|
| |
Telaprevir in Combination with Peginterferon Alfa-2a/Ribavirin in HCV/HIV Co-infected Patients: SVR24 Final Study Results
|
| |
| |
Reported by Jules Levin
AASLD Nov 9-13 2012 Boston
Mark S. Sulkowski1, Kenneth E. Sherman2, Vincent Soriano3, Jürgen K.
Rockstroh4, Douglas T. Dieterich5, Pierre-Marie Girard6, Mohammad
Bsharat7, Joshua Henshaw7, Raymond A. Rubin7, Varun Garg7,
Nathalie Adda7
On behalf of the Study 110 Team
1Johns Hopkins University School of Medicine, Baltimore, MD, United States, 2University of Cincinnati College of Medicine, Cincinnati, OH, United States, 3Hospital Carlos III, Madrid, Spain, 4University of Bonn, Bonn, Germany, 5Mount Sinai School of Medicine, New York, NY, United States, 6Hôpital St Antoine, Paris, France, and 7Vertex Pharmaceuticals Incorporated, Cambridge, MA, United States.
|
| |
|
|
|
|
|
